Apremilast
Total Payments
$288,786
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $288,786 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $288,786 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Apremilast Fed Pilot Study | West-Ward Pharmaceuticals | $144,531 | 0 |
| Apremilast Fasted Pilot Study | West-Ward Pharmaceuticals | $144,256 | 0 |
Top Doctors Receiving Payments for Apremilast
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | — | $288,786 | 2 |
Ad
Manufacturing Companies
- West-Ward Pharmaceuticals $288,786
Product Information
- Type Drug
- Total Payments $288,786
- Total Doctors 0
- Transactions 2
About Apremilast
Apremilast is a drug associated with $288,786 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is West-Ward Pharmaceuticals.
Payment data is available from 2017 to 2017. In 2017, $288,786 was paid across 2 transactions to 0 doctors.
The most common payment nature for Apremilast is "Unspecified" ($288,786, 100.0% of total).
Apremilast is associated with 2 research studies, including "Apremilast Fed Pilot Study" ($144,531).